Active treatment induced a significant reduction in the SNOT-22 score compared with placebo, and in the occurrence of EGPA relapses involving worsening of sinonasal symptoms, indicating that CRS associated with more complex systemic disorders may also benefit from IL-5 targeted therapy. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.